
An Update on Alzheimer Disease: Developments Are Shaping the Future
Big things are happening in Alzheimer disease research. Recent developments are shaping the future for assessment and diagnosis and allowing for early detection and treatment of the disease.
Things are happening in Alzheimer disease (AD) research and there seems to be a lot of excitement in the AD research community. The big news is that recent developments are shaping the future for AD assessment and diagnosis and allowing for early detection and treatment of the disease.
In his presentation at the 2013
The first diagnostic criteria for AD were developed jointly by the
The National Institute on Aging and the Alzheimer Association has now released
• Phase 1: a newly defined stage of preclinical AD
• Phase 2: mild cognitive impairment due to AD
• Phase 3: probable dementia due to AD
The preclinical stage is the time to arrest disease progression, but first it needs to be identified. By Phase 3 there is clear cognitive decline that impairs functional ability in all areas of everyday life.
“Neuropsychological testing is the gold standard to identify the pattern and degree of impairment,” said Dr Agronin, but the new era of biomarkers can provide a means for early detection and intervention. Current evidence shows that measurable biomarker changes in the brain already exist in Phase 1-years before symptoms are detected by the affected individual or by his or her physicians.
Findings indicate that starting medications early and continuing at optimum dose can significantly lower rates of cognitive decline. Dr Agronin suggested that
• Meningiomas
• Alcohol abuse
• Medication-induced cognitive changes
• Bipolar variant with impulse discontrol
• Inattention due to adult ADHD
Although much research is still needed, cautious optimism is warranted. Dr Agronin stressed the need for study participants and urged clinicians to enroll their patients in ongoing studies (ongoing studies can be found at
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.